Achieving glycemic control in elderly patients with type 2 diabetes: a critical comparison of current options

被引:46
作者
Du, Ye-Fong [1 ]
Ou, Horng-Yih [1 ]
Beverly, Elizabeth A. [2 ]
Chiu, Ching-Ju [3 ]
机构
[1] Natl Cheng Kung Univ Hosp, Dept Internal Med, Div Endocrinol & Metab, Tainan 70428, Taiwan
[2] Ohio Univ, Heritage Coll Osteopath Med, Dept Social Med, Athens, OH 45701 USA
[3] Natl Cheng Kung Univ, Coll Med, Inst Gerontol, Tainan 70101, Taiwan
关键词
glycemic target; glycemic variability; blood glucose; frailty; CLINICAL-PRACTICE GUIDELINES; ORAL ANTIDIABETIC DRUGS; METFORMIN PLUS SULFONYLUREA; INITIATING INSULIN THERAPY; IMPAIRED GLUCOSE-TOLERANCE; DIPEPTIDYL PEPTIDASE-IV; VILDAGLIPTIN ADD-ON; OLDER-PEOPLE EDWPOP; LONG-TERM EFFICACY; TO; 75; YEARS;
D O I
10.2147/CIA.S53482
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The prevalence of type 2 diabetes mellitus (T2DM) is increasing in the elderly. Because of the unique characteristics of elderly people with T2DM, therapeutic strategy and focus should be tailored to suit this population. This article reviews the guidelines and studies related to older people with T2DM worldwide. A few important themes are generalized: 1) the functional and cognitive status is critical for older people with T2DM considering their life expectancy compared to younger counterparts; 2) both severe hypoglycemia and persistent hyperglycemia are deleterious to older adults with T2DM, and both conditions should be avoided when determining therapeutic goals; 3) recently developed guidelines emphasize the avoidance of hypoglycemic episodes in older people, even in the absence of symptoms. In addition, we raise the concern of glycemic variability, and discuss the rationale for the selection of current options in managing this patient population.
引用
收藏
页码:1963 / 1980
页数:18
相关论文
共 209 条
[1]   New Approaches to Treating Type 2 Diabetes Mellitus in the Elderly Role of Incretin Therapies [J].
Abbatecola, Aiigela M. ;
Maggi, Stefania ;
Paolisso, Giuseppe .
DRUGS & AGING, 2008, 25 (11) :913-925
[2]   Hypoglycaemic symptoms and hypoglycaemia threshold in older people with diabetes-A patient perspective [J].
Abdelhafiz, A. H. ;
Bailey, C. ;
Loo, B. Eng ;
Sinclair, A. .
JOURNAL OF NUTRITION HEALTH & AGING, 2013, 17 (10) :899-902
[3]   Changes in Prandial Glucagon Levels After a 2-Year Treatment With Vildagliptin or Glimepiride in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy [J].
Ahren, Bo ;
Foley, James E. ;
Ferrannini, Ele ;
Matthews, David R. ;
Zinman, Bernard ;
Dejager, Sylvie ;
Fonseca, Vivian A. .
DIABETES CARE, 2010, 33 (04) :730-732
[4]   Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function [J].
Alba, M. ;
Ahren, B. ;
Inzucchi, S. E. ;
Guan, Y. ;
Mallick, M. ;
Xu, L. ;
O'Neill, E. A. ;
Williams-Herman, D. E. ;
Kaufman, K. D. ;
Goldstein, B. J. .
DIABETES OBESITY & METABOLISM, 2013, 15 (12) :1101-1110
[5]   Metformin-associated lactic acidosis in type 2 diabetes mellitus: incidence and presentation in common clinical practice [J].
Almirall, Jaume ;
Briculle, Meritxell ;
Gonzalez-Clemente, Jose-Miguel .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (07) :2436-2438
[6]  
Ando Yasuyo, 2013, Nihon Rinsho, V71, P1993
[7]  
[Anonymous], LEX DRUGS ONL
[8]  
[Anonymous], 2013, IDF DIABETES ATLAS
[9]  
[Anonymous], 2010, COCHRANE DATABASE SY
[10]  
[Anonymous], 2011, DRUGDEX SYST